ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RUA Rua Life Sciences Plc

11.25
0.10 (0.90%)
12 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Rua Life Sciences Plc LSE:RUA London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.10 0.90% 11.25 288,470 12:44:50
Bid Price Offer Price High Price Low Price Open Price
11.00 11.50 11.25 11.15 11.15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Plastics,resins,elastomers 2.19M -1.44M -0.0232 -4.85 6.92M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:21:03 O 20,000 11.01 GBX

Rua Life Sciences (RUA) Latest News

Rua Life Sciences (RUA) Discussions and Chat

Rua Life Sciences Forums and Chat

Date Time Title Posts
09/11/202408:13RUA Life Sciences - Elast-Eon Enabled MedTech3,768
06/4/202408:54purple the twat is a nasty TROLL24

Add a New Thread

Rua Life Sciences (RUA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:21:0411.0120,0002,202.00O
14:46:2611.1075,0008,325.00O
13:53:0611.482,614299.96O
13:52:0911.382,637299.96O
13:51:3011.384,395499.93O

Rua Life Sciences (RUA) Top Chat Posts

Top Posts
Posted at 12/11/2024 08:20 by Rua Life Sciences Daily Update
Rua Life Sciences Plc is listed in the Plastics,resins,elastomers sector of the London Stock Exchange with ticker RUA. The last closing price for Rua Life Sciences was 11.15p.
Rua Life Sciences currently has 62,060,272 shares in issue. The market capitalisation of Rua Life Sciences is £6,981,781.
Rua Life Sciences has a price to earnings ratio (PE ratio) of -4.85.
This morning RUA shares opened at 11.15p
Posted at 01/11/2024 07:55 by z1co
Posted by NickE on lse:

Good find Jimzi, and often with smaller medical device companies the P/E ratio is usually higher than that of established players. As you say we can't necessarily apply a P/E of around 64 especially as U.S. companies have a higher P/E assigned than UK stocks. Also, the 900k 'fair value' is I assume a temporary boost to the move to profitability although ABISS will accelerate the move to profitability. Regardless, markets look ahead and a value for a high growth medical device company moving to profitability with other increasingly 'oven ready' blue sky products should be a multiple of where we are now.

Following on from the Aortech shareholder base, RUA's history has mainly been in the blue sky sector so value investors probably don't have it on their radar. It's almost as if the stock is punished for being both blue sky and a value play.

It may be that the 50p plus valuation the stock probably deserves will only come with full or partial acquisition and on that topic some very astute posts from IntraVnus.

RUA do tend to drop hints and when they spoke about doubling revenues they didn't allude to the bargain £80k acquisition but the clue was there. Maybe "the Company has changed its financial year end to better guide business planning and international business unit assimilation" is flagging up another acquisition but this time it's RUA itself.

I wonder how that would pan out? They would be interested in contract manufacturing and Elast-Eon but would Coloplast have any need for Rua Vascular and Structural Heart? Unless of course they are looking to expand into long-term implants or soft tissue repair. This quarter could get interesting.
Posted at 30/10/2024 11:05 by z1co
More facts;

The gross assets of Abiss at 31 December 2023 were €2,265,000. Revenue in the year to 31 December 2023 was €2,159,000 up 36% from €1,592,000 during 2023. Loss before tax was €352,000 after depreciation and amortisation charges of €537,000. In the year to 31 December 2023, Abiss had net positive cash flow of €223,000 and cash balances of €279,000 at the year end. Net Assets/Shareholders Funds at 31 December 2023 were €1,624,000. Non-current liabilities totalled €640,000 at 31 December 2023.

Bill Brown, stated: "There are many similarities between Abiss and RUA Contract Manufacture, particularly with a shared customer. Abiss has been pursuing contract manufacture opportunities to further grow its business and the combined strengths of RUA and Abiss should only increase the potential. We very much look forward to working with the Abiss team and integrating into the RUA group."
Posted at 30/10/2024 08:26 by rivaldo
Today's a difficult day to make judgements based on share price reactions - it could just be one or two investors taking profits from the 10.5p-11p area before the Budget changes later on. Or perhaps someone wedded to success re the heart valve has exited given the comment about the MTA partner's priorities.

Personally I'm happiest to see the core trading business apparently thriving with the more speculative elements an added and potentially huge bonus.

I see it's started to bounce now anyway.
Posted at 10/10/2024 16:51 by gleach23
After seeing the small buys at full price I did some dummy trades and noticed hardly any shares available to buy. Then the 111,692 shares trade @ 14.89p was reported 2 hours late to explain it.

Hopefully a sign of retail sellers having been mopped up and that any further buying will put upwards pressure on the share price

The recent chart certainly has a promising look to it.
Posted at 03/10/2024 22:16 by thiopia
Reminder of the prices Directors/Insiders paid in recent years

Directors Deals for Rua Life Sci. (RUA)

Announced Traded Action Notifier Price
14-Dec-22 14-Dec-22 Buy Lachlan Smith 54.17

30-Dec-20 30-Dec-20 Placing Geoffrey Alan Berg 120.00

30-Dec-20 30-Dec-20 Placing John Louis Ely 120.00
Posted at 01/10/2024 09:48 by thiopia
NickE

Today 09:55

Posts: 659

Price: 14.25

They have moved off NT now. Hate to tempt fate but it does look like the main seller is out now and their presence has meant the recent advances and future prospects for the Company hasn't been reflected in the share price.

So it's catch up time along with the prospect of both value enhancing news (due diligence on the acquisition, further contracts for contract manufacturing) and potential transformational news - some form of deal on AurTex whether it be licensing or an outright sale of Structural Heart or the whole .

The latter would quite probably take the share price into 3 figures. Nice risk reward given the seemingly positive strides towards profitability for the group as a whole and a mere 8.4m m/cap.

The management seems driven in their efforts to reach profitability which has meant the stock is a bit of a hidden gem - partly because part of that effort has included cutting costs including not renewing the pr contract with Equity Development
Posted at 17/9/2024 08:04 by rivaldo
Good to see the price responding to some early buying today - nice chart action too with the share price at the highest since early June.
Posted at 08/4/2024 08:41 by rivaldo
Cavendish retain their 25p price target in their update this morning (with a £7.8m m/cap at 12.5p).

Brief extracts:

"Strong strategic progress

RUA Life Sciences has provided a business update for the year to March 2024, noting revenue shortfalls experienced in H1/24 have been made up by a strong second half. Revenues for the year are therefore expected to be in-line with our forecast £2.2m, while the company notes gross margin will exceed our forecasts, with operating costs remaining tightly controlled.

RUA Life Sciences closed FY24 with cash of c£4.0m versus our £3.3m estimate. The company reports significant progress towards its goal of near-term profitability through growing its contract manufacturing business, noting strong progress with a ‘global enterprise’. Finally, RUA has completed a Material Transfer Agreement with a global Heart Valve company covering its composite heart valve material. We believe this update demonstrates excellent progress against the company’s revised strategy."

"Strategy – As noted with its successful fundraise in December 2023, RUA’s revised strategy will seek to grow its Contract Manufacturing business, generating long-term contract revenues, explore third-party funding for its vascular graft portfolio and pursue licence opportunities for its composite heart valve material. We believe this business update demonstrates strong progress against this strategy.

- Investment thesis – We believe the combination of established revenues with growth potential and the option to deliver significant returns through the disruption of established billion-dollar global cardiovascular markets makes RUA Life Sciences an attractive investment opportunity. RUA now aims to turn profitable in the short term and has adopted a strategy to deliver earlier returns on its Vascular and Structural Heart investments."
Posted at 05/4/2024 07:59 by parob
Very good update imo. Plenty of cash/time to get sone commercial deals over the line. Speculation alone could drive this higher. Business Update RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), today provides an update on trading for the financial year ending 31 March 2024 and developments since the successful fundraise in December 2023.TradingThe first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during H1 has been fully compensated by a strong H2 performance. As a result, the Company expects to report, subject to audit, FY24 revenue of £2.2 million, which is in line with market expectations. The Company is pleased to announce that the recovery in revenues has not been at the cost of gross margins, and it is anticipated that reported margins will exceed expectations. The Group has focussed on cost control throughout the year. These rigorous measures are expected to result in operating costs of £3.4 million, approximately £0.2 million below market expectations for the year.Cash PositionStrong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.Business DevelopmentSignificant efforts have been focussed on business development activities as part of the Group's strategy to reach profitability in the short term. It has been the strategy to seek to grow the scale of contract manufacturing, and the Company is pleased to announce that it has succeeded in securing the initial development stages of a significant contract with a global enterprise. This contract represents a major milestone on the route to doubling revenues for the contract manufacturing division once fully operational. Initial development work under this contract has commenced, with an initial purchase order valued at £100,000 already received.Additionally, as announced on 20 December 2023, the Company has successfully entered into a Material Transfer Agreement (MTA) with a global Heart Valve company. The Group's composite material has been delivered and is currently being tested by this partner. The non-calcific nature of Elast-Eon, together with the tear resistance of the novel composite (up to two times improvement over current materials), positions RUA as a leader in developing next-generation alternative leaflet material resistant to Structural Valve Degeneration (SVD). The Company is confident that these results will be of significant interest to other prospective partners and is actively exploring additional potential partnerships.Bill Brown, Chairman of RUA Life Sciences, stated: "Trading results for FY24 represent a meaningful step in delivering on the Group's strategy outlined in November, and the efforts to focus the business on growth are showing promise."Commenting on the Contract Manufacturing success, Bill added:"Securing this contract underscores RUA's expertise in implantable fabrics and moves us closer to profitability. It is our first major contract since the acquisition of RUA Medical Devices in 2020 and supports our belief that there are significant market opportunities in this area."Bill further elaborated on the heart valve composite by stating:"Our material has exceeded expectations, demonstrating remarkable durability and energy efficiency compared to market-leading valves. We are actively seeking partnerships to leverage these compelling results. RUA believes that these outstanding results in preclinical and bench studies are a result of the unique combination of RUA's expertise in medical fabrics and the biostability of Elast-Eon"
Posted at 24/11/2023 11:01 by drradcliffe
What's interesting is Equity Development weren't expecting a trading update. They seemed to think the 20/11/23 Strategy Update replaced a trading update.

From their note 21/11/23:

"Strategy Update In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update."

"Sticking to its objectives In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive."

Does this mean the market itself wasn't expecting this trading update?

I wonder whether it was a very recent decision to do this in order to stabilise the share price, and specifically on a Friday morning to get rid of the short term traders?

If you are going to arrange a small placing, the last thing you want is a highly volatile share price.
Rua Life Sciences share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock